Meeting
2016 ASCO Annual Meeting
Placebo-controlled phase III study comparing dexamethasone on day 1 to on day 1-3 with NK1 receptor antagonist and palonosetoron in high emetogenic chemotherapy.
Authors
Kunihiro Matsuzaki
Department of Pharmacy, St. Marianna University Breast'& Imaging Center, Kawasaki, Japan
Kunihiro Matsuzaki , Yuka Ito , Mamoru Fukuda , Kentaro Sakamaki , Masahiko Ando , Yasuyuki Kojima , Naoki Furuya , Takashi Tsuda , Hiroko Minatogawa , Yasushi Ichikawa , Ichiro Ohta , Saori Takei , Yutaka Tokuda , Kazutaka Narui , Ayako Tsuboya , Takashi Suda , Satoshi Morita , Takeharu Yamanaka , Narikazu Boku , Takako Eguchi Nakajima
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
UMIN000008867
Citation
J Clin Oncol 34, 2016 (suppl; abstr 10019)
DOI
10.1200/JCO.2016.34.15_suppl.10019
Abstract #
10019
Poster Bd #
7
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase III study of NEPA, a fixed combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV).
First Author: Li Zhang
Poster
2017 Palliative and Supportive Care in Oncology Symposium
Phase III study of palonosetron (PALO) given as 30-min IV infusion (IV inf) versus 30-sec IV bolus (IV bol) for prevention of chemotherapy-induced nausea and vomiting (CINV) associated with highly emetogenic chemotherapy (HEC).
First Author: Meinolf Karthaus
Poster
2013 ASCO Annual Meeting
Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).
First Author: Matti S. Aapro
Poster
2011 ASCO Annual Meeting
Phase III study of single-dose casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting.
First Author: P. J. Hesketh